David Malcom Rodman, serving as the Chief Medical Officer for Mineralys Therapeutics, Inc., executed a transaction involving the sale of 2,171 shares of the company's common stock on July 9, 2026. The aggregate value of this sale reached $65,781, with each share transacted at a price point of $30.30. This divestment was facilitated through a Rule 10b5-1 trading plan, a mechanism designed to allow executives to buy or sell shares in compliance with insider trading regulations. Mr. Rodman initially adopted this specific trading plan on October 6, 2025, establishing the framework for these subsequent transactions.
The timing of this sale is notable given the stock's recent performance. Over the preceding twelve months, Mineralys Therapeutics shares delivered a return of 94%, reflecting significant market movement. However, at the time of the transaction, the stock was trading at $28.36, which places the current market price below the $30.30 price at which Mr. Rodman executed his sale. According to analysis provided by InvestingPro, the current valuation levels suggest the stock may be overvalued relative to its fundamentals.
In a concurrent activity on the same day, prior to the execution of the sale, Mr. Rodman acquired an identical quantity of 2,171 shares through the exercise of stock options. These shares were obtained at a fixed exercise price of $16.00 per share, resulting in a total transaction value of $34,736. The specific stock options utilized for this acquisition carried a conversion or exercise price of $16.00 and are scheduled to expire on February 9, 2033. The vesting schedule for these options was structured such that 25% of the underlying shares vested on the first anniversary of the grant date, with the remaining balance vesting in 36 substantially equal monthly installments thereafter.
Following the completion of these transactions, Mr. Rodman's direct holdings in Mineralys Therapeutics common stock stand at 57,733 shares. This total holding figure incorporates 638 shares that were purchased under the Mineralys Therapeutics, Inc. 2023 Employee Stock Purchase Plan but had not been previously reported in prior disclosures. Additionally, his portfolio includes 15,194 derivative shares in the form of stock options. Investors utilizing InvestingPro subscriptions have access to eight additional exclusive tips regarding MLYS, which include detailed Pro Research Reports designed to convert complex data into actionable intelligence for investment decisions.
Market data indicates that MLYS closed at $28.36, representing a decline of $0.60 or 2.07% from the previous close. After-hours trading showed a further minor decline to $28.15, a drop of $0.23 or 0.81%. The stock's performance over various timeframes, including one day, one week, one month, six months, one year, five years, and maximum duration, is tracked through analytical tools provided by the platform.
In broader corporate developments, Mineralys Therapeutics announced the pricing of a public offering comprising 5,660,378 shares of common stock at $26.50 per share. This offering is expected to generate approximately $150 million in gross proceeds. Concurrently, the company secured up to $750 million through a combination of debt, equity, and a royalty deal. This capital structure is aimed at repurchasing royalty obligations and strengthening the company's balance sheet. As part of this transaction, Mineralys will pay Tanabe Pharma Corporation $200 million upfront, with potential additional payments contingent upon commercial milestones, to eliminate future royalty payments related to the drug lorundrostat.
Analyst coverage reflects mixed perspectives on the company's trajectory. Jefferies reiterated a Hold rating on Mineralys stock, setting a price target of $30.00. This rating comes amid market speculation regarding a potential acquisition during the FDA review of the company's new drug application. Conversely, H.C. Wainwright maintained a Buy rating with a more aggressive price target of $56.00. This bullish outlook highlights the company's presentation of post hoc analysis from the Launch-HTN trial at a European conference. Mineralys also presented clinical data for lorundrostat, evaluating its efficacy in participants with uncontrolled or resistant hypertension, including those suffering from chronic kidney disease. These clinical and strategic developments underscore ongoing progress within the company's pipeline and financial restructuring efforts.